Umoja Biopharma to Unveil Preliminary Positive Non-Human Primate Data for the First Time at the 8th CAR-TCR Summit
23 août 2023 10h00 HE
|
Umoja Biopharma, Inc.
SEATTLE, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for cancers, today announced it will unveil preliminary...
Umoja Biopharma to Present at the 2023 BIO International Convention
31 mai 2023 10h17 HE
|
Umoja Biopharma, Inc.
SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematological cancers, today announced that...
Umoja Biopharma Presents New Preclinical Data at the American Society of Gene and Cell Therapy 26th Annual Meeting Demonstrating Potent In Vivo CAR T Cell Generation and Durable Anti-Tumor Activity
17 mai 2023 09h00 HE
|
Umoja Biopharma, Inc.
UB-VV200 preclinical data highlight successful generation of TagCAR T cells, which demonstrate dose-dependent anti-tumor activity when used in combination with TumorTag™ technology in an in vivo model...
Umoja Biopharma to Present New Data at the American Society of Gene and Cell Therapy 26th Annual Meeting
03 mai 2023 08h00 HE
|
Umoja Biopharma, Inc.
SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid...
Umoja Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 10h00 HE
|
Umoja Biopharma, Inc.
SEATTLE, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with...
Umoja Biopharma Appoints Dieter Weinand as the Chair of its Board of Directors
14 déc. 2022 07h30 HE
|
Umoja Biopharma, Inc.
SEATTLE, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with...
Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies
21 nov. 2022 08h00 HE
|
Umoja Biopharma, Inc.
SEATTLE and SAN JOSE, Calif. and SHANGHAI, China and NANJING, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated...
Umoja Biopharma Presents New Preclinical Data on its Integrated In Vivo CAR T and Engineered Induced Pluripotent Stem Cell Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
10 nov. 2022 09h00 HE
|
Umoja Biopharma, Inc.
New data shows that CAR T cells engineered in vivo with VivoVec particles mediate durable antitumor activity Potent and durable anti-tumor activity demonstrated with a universal TagCAR targeted...
Umoja Biopharma to Present Three Posters Data on its Integrated In Vivo CAR T and ShRED Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
19 oct. 2022 08h00 HE
|
Umoja Biopharma, Inc.
SEATTLE, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients...
Umoja Biopharma Appoints Igor I. Slukvin, M.D., Ph.D. to its Scientific Advisory Board
13 sept. 2022 09h00 HE
|
Umoja Biopharma, Inc.
SEATTLE, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients...